These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38285957)

  • 1. Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.
    Garvey WT; Cohen RM; Butera NM; Kazemi EJ; Younes N; Rosin SP; Suratt CE; Ahmann A; Hollander PA; Krakoff J; Martin CL; Seaquist E; Steffes MW; Lachin JM;
    Diabetes Care; 2024 Apr; 47(4):562-570. PubMed ID: 38285957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
    ; Nathan DM; Lachin JM; Balasubramanyam A; Burch HB; Buse JB; Butera NM; Cohen RM; Crandall JP; Kahn SE; Krause-Steinrauf H; Larkin ME; Rasouli N; Tiktin M; Wexler DJ; Younes N
    N Engl J Med; 2022 Sep; 387(12):1063-1074. PubMed ID: 36129996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    Wexler DJ; de Boer IH; Ghosh A; Younes N; Bebu I; Inzucchi SE; McGill JB; Mudaliar S; Schade D; Steffes MW; Tamborlane WV; Tan MH; Ismail-Beigi F;
    JAMA Intern Med; 2023 Jul; 183(7):705-714. PubMed ID: 37213109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Gonzalez JS; Bebu I; Krause-Steinrauf H; Hoogendoorn CJ; Crespo-Ramos G; Presley C; Naik AD; Kuo S; Johnson ML; Wexler D; Crandall JP; Bantle AE; Arends V; Cherrington AL;
    Diabetes Care; 2024 Apr; 47(4):610-619. PubMed ID: 38416773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
    Deng Y; Polley EC; Wallach JD; Dhruva SS; Herrin J; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Lyon TD; Shah ND; Ross JS; McCoy RG
    BMJ; 2022 Oct; 379():e070717. PubMed ID: 36191949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.
    Utzschneider KM; Younes N; Butera NM; Balasubramanyam A; Bergenstal RM; Barzilay J; DeSouza C; DeFronzo RA; Elasy T; Krakoff J; Kahn SE; Rasouli N; Valencia WM; Sivitz WI;
    Diabetes Care; 2024 Apr; 47(4):571-579. PubMed ID: 38190619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Kirkman MS; Tripputi M; Krause-Steinrauf H; Bebu I; AbouAssi H; Burch H; Duran-Valdez E; Florez H; Garvey WT; Hsia DS; Salam M; Pop-Busui R;
    Diabetes Care; 2024 Apr; 47(4):594-602. PubMed ID: 38194519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve and maintain good glycemic control?].
    Lanthier L; Mutchmore A; Plourde MÉ; Cauchon M
    Rev Med Interne; 2023 Jan; 44(1):48-49. PubMed ID: 36443201
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Wexler DJ; Krause-Steinrauf H; Crandall JP; Florez HJ; Hox SH; Kuhn A; Sood A; Underkofler C; Aroda VR;
    Diabetes Care; 2019 Nov; 42(11):2098-2107. PubMed ID: 31391203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Hollander PA; Krause-Steinrauf H; Butera NM; Kazemi EJ; Ahmann AJ; Fattaleh BN; Johnson ML; Killean T; Lagari VS; Larkin ME; Legowski EA; Rasouli N; Willis HJ; Martin CL;
    Diabetes Care; 2024 Apr; 47(4):638-645. PubMed ID: 37756542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
    Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    Rasouli N; Younes N; Ghosh A; Albu J; Cohen RM; DeFronzo RA; Diaz E; Sayyed Kassem L; Luchsinger JA; McGill JB; Sivitz WI; Tamborlane WV; Utzschneider KM; Kahn SE;
    Diabetes Care; 2024 Apr; 47(4):580-588. PubMed ID: 38211595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    ; Nathan DM; Lachin JM; Bebu I; Burch HB; Buse JB; Cherrington AL; Fortmann SP; Green JB; Kahn SE; Kirkman MS; Krause-Steinrauf H; Larkin ME; Phillips LS; Pop-Busui R; Steffes M; Tiktin M; Tripputi M; Wexler DJ; Younes N
    N Engl J Med; 2022 Sep; 387(12):1075-1088. PubMed ID: 36129997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Cherrington AL; Tripputi MT; Younes N; Herman WH; Katona A; Groessl EJ; Craig J; Gonzalez JS; Garg R; Casula S; Kuo S; Florez HJ;
    Diabetes Care; 2024 Apr; 47(4):603-609. PubMed ID: 38190625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.